ViewRay, Inc. – NASDAQ:VRAY

Add to watchlist

$0.025

+0.01

+94.57%

Market closed

Open in about 11 hours

-97.17%

month

-98.03%

quarter

-99.66%

year

Market Cap	N/A
Enterprise value	501.99M

P/E	-5.4
EV/Sales	4.91
EV/EBITDA	-5.15
Price/Sales	5.44
Price/Book	6.76
PEG ratio	-0.26
EPS	-0.63

Revenue	105.86M
EBITDA	-100.58M
Income	-114.17M
Revenue Q/Q	19.37%
Revenue Y/Y	44.09%

Profit margin	-105.01%
Oper. margin	-104.81%
Gross margin	9.83%
EBIT margin	-104.81%
EBITDA margin	-95.01%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

ViewRay, Inc. (NASDAQ:VRAY): Profit margin
Jun 2022	22.14M	-27.29M	-123.22%
Sep 2022	26.49M	-28.29M	-106.83%
Dec 2022	34.69M	-27.86M	-80.33%
Mar 2023	22.53M	-30.71M	-136.3%

ViewRay, Inc. (NASDAQ:VRAY): Earnings per share (EPS)
2023-05-04	-0.16	-0.14

ViewRay, Inc. (NASDAQ:VRAY): Debt to assets
Jun 2022	277044000	152.22M	54.95%
Sep 2022	260211000	155.95M	59.93%
Dec 2022	271397000	189.15M	69.7%
Mar 2023	233159000	177.90M	76.3%

ViewRay, Inc. (NASDAQ:VRAY): Cash Flow
Jun 2022	-21.94M	-1.44M	929K
Sep 2022	-14.37M	-950K	9K
Dec 2022	-22.99M	-282K	18.90M
Mar 2023	-53.59M	-1.17M	-2.18M

ViewRay alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

ViewRay, Inc. (NASDAQ:VRAY): Employee count
Aug 2023	295
Sep 2023	295
Oct 2023	295
Nov 2023	295
Dec 2023	295
Jan 2024	295
Feb 2024	295
Mar 2024	295
Apr 2024	295
May 2024	295
Jun 2024	295
Jul 2024	295

ViewRay
Hedge Funds Holdings Q1 2023

48.11% -29.37%

of VRAY is owned by hedge funds

107 -65

hedge funds hold VRAY stock

86.93M -53.33M

shares is hold by hedge funds

VRAY hedge funds holdings changes

ViewRay, Inc. (NASDAQ:VRAY): Insider trades (number of shares)
Period	Buy	Sel
Nov 2022	25000	0
Mar 2023	0	42000
Jul 2023	0	13285227

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	21 Jul 2023	SHAH SANKET officer: SVP, General Counsel officer: SVP, General Counsel	Common Stock	30,364	$0.08	$2,277
Sale	21 Jul 2023	JOHNSON B KRISTINE director director	Common Stock	30,702	$0.05	$1,597
Sale	21 Jul 2023	PRANGE KAREN director director	Common Stock	37,600	$0.05	$1,918
Sale	20 Jul 2023	EBRAHIMI FARHAD FRED 10 percent owner 10 percent owner	COMMON STOCK	1,852,262	$0.06	$111,136
Sale	20 Jul 2023	EBRAHIMI FARHAD FRED 10 percent owner 10 percent owner	COMMON STOCK	3,886,848	$0.06	$233,211
Sale	20 Jul 2023	EBRAHIMI FARHAD FRED 10 percent owner 10 percent owner	COMMON STOCK	417,500	$0.06	$25,050
Sale	20 Jul 2023	EBRAHIMI FARHAD FRED 10 percent owner 10 percent owner	COMMON STOCK	122,500	$0.06	$7,350
Sale	20 Jul 2023	EBRAHIMI FARHAD FRED 10 percent owner 10 percent owner	COMMON STOCK	322,500	$0.06	$19,350
Sale	20 Jul 2023	EBRAHIMI FARHAD FRED 10 percent owner 10 percent owner	COMMON STOCK	1,400,000	$0.06	$84,000
Sale	19 Jul 2023	CASTELEIN CALEY director director	Common Stock	158,397	$0.07	$10,771

ViewRay
Earnings Call Transcripts

Quarter	Transcript
Q1 2023 12 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 27 Feb 2023	Q4 2022 Earnings Call Transcript
Q3 2022 1 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 2 Aug 2022	Q2 2022 Earnings Call Transcript

VRAY earnings call transcripts

ViewRay
Executives

Insider	Age	Compensation
Mr. Scott William Drake (1968) Pres, Chief Executive Officer & Director	57	$1,410,000
Dr. James F. Dempsey (1971) Chief Scientific Officer	54	$523,090
Mr. Zachary William Stassen (1979) Chief Financial Officer	46	$413,080

ViewRay
Latest News

Wednesday, 18 October 2023
17:03	Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers—Let's Preserve ViewRay Technology	businesswire.com
Tuesday, 17 October 2023
09:04	Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies	businesswire.com
Friday, 13 October 2023
10:46	Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies	businesswire.com
Friday, 21 July 2023
16:01	ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets	prnewswire.com
Monday, 17 July 2023
10:41	Why Is ViewRay (VRAY) Stock Down 69% Today?	InvestorPlace
Friday, 26 May 2023
08:56	Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)	Benzinga
Wednesday, 10 May 2023
18:59	ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Thursday, 13 April 2023
19:28	ViewRay: Shares Crater As Company Warns Of Slower Growth, Higher Cash Burn	Seeking Alpha
Wednesday, 12 April 2023
17:25	ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023	PRNewsWire
Friday, 31 March 2023
11:16	Penny Stocks To Buy Now? 7 With Unusual Options Volume This Week	PennyStocks
Monday, 27 February 2023
20:42	ViewRay, Inc. (VRAY) Q4 2022 Earnings Call Transcript	Seeking Alpha
19:34	ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates	Zacks Investment Research
Sunday, 12 February 2023
23:32	ViewRay: Sales, Order Momentum Ratcheting Higher	Seeking Alpha
Tuesday, 31 January 2023
06:30	ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023	PRNewsWire
Thursday, 24 November 2022
09:25	ViewRay: Revise Thesis To Buy, Multiple Upside Targets In Place	Seeking Alpha
Thursday, 10 November 2022
06:30	ViewRay® to Present at the Stifel 2022 Healthcare Conference	PRNewsWire
Tuesday, 1 November 2022
20:44	ViewRay, Inc. (VRAY) Q3 2022 Earnings Call Transcript	Seeking Alpha
Friday, 14 October 2022
06:30	ViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022	PRNewsWire
Friday, 9 September 2022
06:30	ViewRay® to Present at the Morgan Stanley 20th Annual Global Healthcare Conference	PRNewsWire
Tuesday, 2 August 2022
21:40	ViewRay, Inc. (VRAY) CEO Scott Drake on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
18:51	ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 19 July 2022
06:30	ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022	PRNewsWire
Thursday, 26 May 2022
13:33	What Makes ViewRay (VRAY) a New Buy Stock	Zacks Investment Research
Sunday, 8 May 2022
03:08	ViewRay, Inc.'s (VRAY) CEO Scott Drake on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 5 May 2022
18:48	ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Thursday, 24 February 2022
22:04	ViewRay, Inc. (VRAY) CEO Scott Drake on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
19:15	ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 5 January 2022
11:30	Wall Street Analysts Predict a 38% Upside in ViewRay (VRAY): Here's What You Should Know	Zacks Investment Research
Sunday, 7 November 2021
16:47	ViewRay, Inc.'s (VRAY) CEO Scott Drake on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 4 November 2021
19:49	ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 13 Apr 2023

ViewRay: Shares Crater As Company Warns Of Slower Growth, Higher Cash Burn
Seeking Alpha 13 Feb 2023

ViewRay: Sales, Order Momentum Ratcheting Higher
Seeking Alpha 24 Nov 2022

ViewRay: Revise Thesis To Buy, Multiple Upside Targets In Place
Seeking Alpha 26 Jul 2022

ShockWave Medical: A Hidden Gem In The Medical Device Sector
Seeking Alpha 17 May 2022

Insider Weekends: First Insider Purchase At Starbucks In Nearly 4 Years
Seeking Alpha 29 Mar 2021

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Frequently Asked Questions (FAQ)

What's the price of ViewRay stock today?

One share of ViewRay stock can currently be purchased for approximately $0.03.
When is ViewRay's next earnings date?

Unfortunately, ViewRay's (VRAY) next earnings date is currently unknown.
Does ViewRay pay dividends?

No, ViewRay does not pay dividends.
What is ViewRay's stock symbol?

ViewRay, Inc. is traded on the NASDAQ under the ticker symbol "VRAY".
What is ViewRay's primary industry?

Company operates in the Healthcare sector and Medical - Devices industry.
How do i buy shares of ViewRay?

Shares of ViewRay can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are ViewRay's key executives?
ViewRay's management team includes the following people:
- Mr. Scott William Drake Pres, Chief Executive Officer & Director(age: 57, pay: $1,410,000)
- Dr. James F. Dempsey Chief Scientific Officer(age: 54, pay: $523,090)
- Mr. Zachary William Stassen Chief Financial Officer(age: 46, pay: $413,080)
How many employees does ViewRay have?

As Jul 2024, ViewRay employs 295 workers.
When ViewRay went public?

ViewRay, Inc. is publicly traded company for more then 10 years since IPO on 10 Aug 2015.
What is ViewRay's official website?

The official website for ViewRay is viewray.com.
Where are ViewRay's headquarters?

ViewRay is headquartered at 2 Thermo Fisher Way, Oakwood, OH.
How can i contact ViewRay?

ViewRay's mailing address is 2 Thermo Fisher Way, Oakwood, OH and company can be reached via phone at +44 7033210.

ViewRay, Inc.

viewray.com

Exchange:

NASDAQ

Full time employees:

295

Industry:

Medical - Devices

Sector:

Healthcare

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

+44 7033210

2 Thermo Fisher Way
Oakwood, OH 44146

CIK: 0001597313
ISIN: US92672L1070
CUSIP: 92672L107